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Abstract
Objective. To investigate the distribution of inhibitory killer cell immunoglobulin-like receptor (iKIR) and its ligand 
human leukocyte antigen C locus (HLA-Cw) in patients with inflammatory bowel disease (IBD), and explore whether 
iKIR/HLA-Cw combinations are associated with IBD susceptibility. Methods. The iKIR in 100 patients with ulcerative 
colitis (UC), 52 patients with Crohn’s disease (CD) and 106 randomly ethnically matched healthy controls was pheno-
typed by sequence-specific primer PCR (PCR-SSP). HLA-Cw was phenotyped by CLOCUS SSP UNITRAY®. The com-
bination of HLA-Cw and its corresponding iKIR in individual was analyzed subsequently. Results. The KIR2DL1 and 
KIR2DL3 gene phenotype frequencies in UC patients were 0.710 and 0.620 respectively, both significantly lower than 
those in healthy controls, and the KIR2DL1 gene phenotype frequency in CD patients was 0.731, significantly lower than 
that in healthy controls.  KIR2DL1-HLA-C2 combination in patients with UC and CD were 0.380 and 0.404 respectively, 
both significantly lower than that in healthy controls. Conclusion. The susceptibility to IBD is associated with decreased 
KIR2DL1-HLA-C2 combination. [Life Science Journal. 2008; 5(4): 17 – 22] (ISSN: 1097 – 8135).
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1  Introduction
Crohn’s disease (CD) and ulcerative colitis (UC), also 
known as inflammatory bowel disease (IBD), are char-
acterized by chronic inflammation of the gastrointestinal 
tract. While the causes of IBD are unknown, it is thought 
that inflammation results from an inappropriate chronic 
activation of the innate and adaptive mucosal immune 
systems in a genetically susceptible host[1] and that enteric 
microflora plays a central role in the initiation and mainte-
nance of disease. Epidemiological and genetic research has 
provided firm evidence for the existence of genetic deter-
minants of susceptibility to IBD, and raised expectations 
that the identification of IBD susceptibility genes may lead 
to a clearer understanding of pathogenesis, and ultimate-
ly better treatment. Genome-wide screening in UC has
demonstrated replicated linkage to several chromosomal 
regions, including regions on chromosomes 6, and 19 
termed IBD3 and IBD6, respectively[2,3]. The killer cell im-
munoglobulin-like receptor (KIR) gene family is located 
within the IBD6 linkage region at chromosome 19q13.4. 
KIRs are expressed on natural killer cells and subsets of 
γδ+ T cells and memory and effector αβ+ T cells (usually 
CD8+ T cells and some CD4+ T cells), and can be divided 
on functional grounds into inhibitory and activating re-
ceptors. KIR possess a variety of inhibitory and activating 
receptors that upon recognizing and binding to their HLA 
class I ligands on target cells, regulate activation and in-
hibition of NK cell responses. Inhibitory receptors with 
specificity for human leukocyte antigen (HLA) class I ap-
pear to be important mediators of self-tolerance for NK 
cells. iKIR with the appropriate HLA ligand induces in-
hibitory signal depending on the presence of intracellular 
immunoregulatory tyrosine-based inhibitory motifs, pro-
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tecting self cell from the attack of natural killer (NK) cell. 
HLA class I are encoded on chromosomes 6p21.3. 
HLA class I molecules are expressed on the surface of 
nearly all nucleated cells and mediate interactions with T 
lymphocytes, which recognize peptides bound to class I 
molecules, and NK cells, which recognize particular al-
lelic forms of class I molecules. As with their MHC class 
I ligands, the population diversity and rapid evolution of 
the KIR genes strongly suggests that they are under patho-
gen-mediated selection[4]. It has been documented that al-
terations in the expression of KIR repertoire on NK cells 
as well as its corresponding ligand are associated with 
autoimmune diseases[5,6]. Combinations of KIR and HLA 
class I ligand variants that reduce NK cell inhibition have 
been shown to increase susceptibility to autoimmune dis-
eases as well as resistance towards infections[6–10]. HLA C 
locus (HLA-Cw) molecules belong to classical HLA class 
I,  and KIR-HLA-Cw molecule interactions are important 
for KIR recognizing target cells. Recent studies suggest 
that IBD may share an underlying pathogenesis with other 
autoimmune diseases. A much higher risk for rheumatoid 
arthritis (RA), ankylosing spondylitis (AS), psoriatic ar-
thritis (PsA) and multiple sclerosis (MS) was observed 
in IBD patients compared with controls[11]. This promotes 
us to investigate whether KIR gene and HLA-Cw alleles 
play roles in the regulation of autoimmunity for IBD. In 
this study, we investigated the distribution of iKIR and its 
ligand HLA-Cw in patients with IBD, and explore wheth-
er iKIR-HLA-Cw combinations are associated with IBD 
susceptibility.
2  Materials and Methods
2.1 Subjects
The study included 100 patients with UC, 52 patients 
with CD and 106 randomly geographically and ethnically 
matched healthy controls. The patients were recruited 
from the Second Affiliated Hospital of Zhengzhou Uni-
versity in China. IBD was diagnosed and classified ac-
cording tostandard clinical, endoscopic or radiological, 
and histological criteria criteria. Median age at diagnosis 
of IBD was 41.3 years old (range 16 – 81). Detailed demo-
graphic and clinical information were obtained and whole 
blood was taken for DNA extraction and subsequent ge-
netic analysis. An ethnically and gender-matched group 
of healthy controls was randomly selected from blood 
donors and general practice registers, with ages ranging 
from 17 to 79 years, with an average of 41.5 years.
2.2 DNA preparation
Genomic DNA was extracted from whole blood using 
a Relax Gene Blood DNA system (TIANGEN, China). 
Yielding high molecular DNA validated for genotyping 
purposes.
2.3 KIR genotyping 
The KIR genotyping was performed by means of se-
quence specific primer PCR (PCR-SSP) in all the recruited 
subjects for the following iKIRs: KIR2DL1, KIR2DL2, 
KIR2DL3, KIR2DL4, KIR2DL5, KIR3DL1, KIR3DL2 
and KIR3DL3. The sequence specific polymorphism 
primers used for the detection of iKIR loci were based 
on primer sites that have been previously described[12–14]. 
The sequences and positions of the different primers were 
listed in Table 1. All reactions contained internal control 
primers specific for human growth hormone. All prim-
ers were synthesized and validated by Sangon Biological 
Engineering Technology and Service Co. Ltd (Shanghai, 
China). Each experiment included negative control reac-
tions containing distilled water as a template. KIR specific 
primers were used at a final concentration of 0.4 μM. Am-
plifications of KIR genes were performed in 25 μl reac-
tions, 0.75 U Taq Polymerase (Promega, USA), 0.2 mM 
dNTPs (Takara, Japan), 2 mM MgCl2 , 50 ng/μl of genom-
ic DNA. All were under the following conditions except 
for KIR2DL2 and KIR3DL2: initial denaturation at 95 ºC 
for 2 minutes, then 30 seconds at 95 ºC, 30 seconds at 65 
ºC, 1.5 minutes at 72 ºC for 30 cycles, and a final exten-
sion of 5 minutes at 72 ºC. KIR2DL2 and KIR3DL2 was 
carried out under the following conditions: at 95 ºC for 2 
minutes, then 30 seconds at 95 ºC, 30 seconds at 63 ºC, 
1.5 minutes at 72 ºC for 30 cycles, and a final extension of 
5 minutes at 72 ºC. Amplification products were analyzed 
by the presence or absence of an electrophoretic specific 
band in 2% agarose gel stained with ethidium bromide in 
0.5 × TBE buffer and visualized by ultraviolet light.
2.4 HLA genotyping
HLA-Cw genotyping of all subjects were performed 
using the HLA-C LOCUS SSP UNITRAY® typing kits 
(Invitrogen, USA). Low resolution PCR-SSP sets was 
used for typing according to the manufacturer’s instruc-
tions. The kit was commercialized which used 23 pairs 
of locus-specific primers, and one negative control by 
the manufacturer. Alleles were assigned using the Pat-
tern Matching Program provided by Dynal (Invitrogen, 
USA).
2.5 Statistical analysis
Gene frequencies were calculated with the formula of 
Hsu et al[13]. Briefly, observed frequencies of KIR genes 
were determined by the ratio of gene presence within the 
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population to the total population number. KIR gene fre-
quencies were estimated by the formula: gene frequency 
= 1 – (1 – f)1/2, where f stands for the observed KIR gene 
frequency in the population. Associations of presence or 
absence of single HLA-C and KIR alleles and receptor-
ligand pairings were assessed using chi-square tests from 
two-by-two contingency tables. The statistical package 
SPSS, version 10.0 was used for analyses.
3  Results
3.1 KIR phenotypic frequency and genotypic frequen-
cies in patients and control subjects
We genotyped both cohorts for the presence or absence 
of all 8 iKIR genes and their HLA-Cw ligand epitopes. 
The phenotype frequencies of iKIR loci and HLA-Cw 
epitopes were displayed in Table 2. The framework genes 
KIR2DL4, KIR3DL2 and KIR3DL3 were present in all 
individuals. The KIR2DL1 and KIR2DL3 gene pheno-
type frequencies in UC patients were 0.710 and 0.620 re-
spectively, both significantly lower than those in healthy 
controls (P = 0.001). The KIR2DL1 gene phenotype fre-
quency in CD patients was 73.1%, significantly lower 
than that in healthy controls (P = 0.007), and none of the 
other iKIR differed significantly. iKIR PCR-SSP geno-
typing were shown in Figure 1. An example of HLA-Cw 
typing was shown in Figure 2.
3.2 Decreased frequency of HLA-C group 2 alleles in 
individuals with UC
According to previous reports, HLA-C was divided into 
group 1 or group 2 depending on whether there was an as-
paragine or lysine present at position 80 of the 1 domain. 
In this study, HLA-C2 phenotype frequencies were sig-
nificantly lower in UC group than in healthy controls (P = 
0.02). The HLA-C1 phenotype frequencies in IBD patients 
Table 2. Phenotype frequencies of iKIR and HLA-Cw
 in UC and CD
item UC (n = 100) CD (n = 52) Controls (n = 106)
iKIR
KIR2DL1 0.710* 0.731** 0.896
KIR2DL2 0.150 0.154 0.170
KIR2DL3 0.620* 0.769 0.821
KIR2DL4 1.000 1.000 1.000
KIR2DL5 0.230 0.192 0.198
KIR3DL1 1.000 0.962 0.972
KIR3DL2 1.000 1.000 1.000
KIR3DL3 1.000 1.000 1.000
HLA-Cw
HLA-C1 0.830 0.808 0.811
HLA-C2 0.520# 0.519 0.641
vs. healthy controls: *P = 0.001,** P = 0.007,  # P = 0.02.
Figure 1.  iKIR genotyping: Positive for the following iKIR from 
Lane 1 to Lane 8: KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, 
KIR2DL5, KIR3DL1, KIR3DL2, KIR3DL3; M: molecular mass 
marker. 
did not significantly differ from those in healthy controls.
3.3 The combination of HLA-Cw and iKIR in IBD
Receptor effector function depend on the presence of 
corresponding ligand. Individuals who express simultane-
ously iKIR and its corresponding HLA-Cw ligand have 
Table 1.  iKIR gene primer sequence
iKIR gene Sense (5' – 3') Antisense (5' – 3') Amplication (bp)
KIR2DL1 CTGTTACTCACTCCCCCTATCAGG AGGGCCCAGAGGAAAGTCA 1770
KIR2DL2 CATGATGGGGTCTCCAAA CCCTGCAGAGAACCTACA 1808
KIR2DL3 CCTTCATCGCTGGTGCTG CAGGAGACAACTTTGGATCA 812
KIR2DL4 CCCCTCAACAGATACCAGCGTGTG GCAGGCAGTGGGGACCTTAGACA 271
KIR2DL5 GCTCTTCTTTCTCCTTCATTGCTGC GCAGGCAGTGGGGACCTTAGACA 1025
KIR3DL1 AAGACACCCCCTACAGATACCATCT GCAGGCAGTGGGGACCTTAGACA 277
KIR3DL2 TCCTGTCTGCCCGGCCCAGCA ACCCAGTGAGGGAGTGTG 228
KIR3DL3 AACACGGAACTTCCAAATGCTGAGCG GCAGGCAGTGGGGACCTTAGACA 243
HGH GCCTTCCCAACCATTCCCTTA TCACGGATTTCTGTTGTGTTT 429
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Table 3. The phenotype frequency of iKIR-HLA-Cw in patients 
with IBD and healthy controls





2DL1+/HLA-C2+ 0.380* 0.404** 0.575
2DL1+/HLA-C2– 0.330 0.327 0.321
2DL1–/HLA-C2+ 0.1000 0.115 0.066
2DL1–/HLA-C2– 0.190# 0.154## 0.038
2DL2 and/or 2DL3+/HLA-C1+ 0.630 0.654 0.698
2DL2 and/or 2DL3+/HLA-C1– 0.060 0.135 0.132
2DL2 and 2DL3–/HLA-C1+ 0.200 0.154 0.113
2DL2 and 2DL3–/HLA-C1– 0.110 0.058 0.057
vs. healthy controls: *P = 0.05,** P = 0.042,  # P = 0.001, ## P = 0.023.
inhibitory function. From Table 3, we found that indi-
vidual inhibitory KIR-HLA genotypes differ significantly 
between IBD patients and controls. KIR2DL3-HLA-C1 
is dominant in IBD patients and controls. The pheno-
type frequency of KIR2DLl-HLA-C2 combination was 
38% (UC) and 40.4% (CD), respectively. The inhibitory 
KIR2DL1-HLA-C2 genotypes were less frequently pres-
ent in UC (P = 0.005) and CD (P = 0.042) patients than 
control subjects. 19.0% UC patients and 15.4% CD pa-
tients lack KIR-HLA-C2 (P = 0.001, P = 0.023, respec-
tively), significantly different from the controls. The phe-
notype frequencies of KIR2DL2/KIR2DL3 and HLA-C1 
combination in IBD patients did not significantly differ 
from those in healthy controls. 
4  Discussion
NK cell effector function is perceived to be an impor-
tant first line of innate immunity across viral, bacterial 
and parasitic infections, as well as forming an important 
bridge for activation of the adaptive immune response[15]. 
NK cell function is regulated by the balance between ac-
tivating and inhibitory receptors in a majority of cases, 
interacting with HLA class I molecules. KIRs on NK cells 
and their ligands, HLA class I molecules, play an essen-
tial part in this tight regulation. Individual differences in 
NK cell interactions are dependent on combinations of 
variable KIR and HLA class I gene products[16]. Different 
receptor-ligand interactions may result in altered NK cell 
mediated immunity against pathogens[17]. An emerging 
body of evidence is accumulating to suggest that KIRs 
and HLA class I ligands contribute to the pathogenesis 
of diverse kinds of autoimmune diseases such as RA[18], 
AS[19], PsA[9], systemic lupus erythematosus (SLE) and 
Scleroderma[20].
The human KIR gene family contains 15 genes and 
2 pseudogenes that are closely linked on chromosome 
19q13.4. The number of KIR genes in the genome of 
any given individual varies within the population. KIRs 
contain either two or three immunoglobulin-like domains 
with either long (2DL, 3DL) or short (2DS, 3DS) cyto-
plasmic tails[21]. The presence of a long cytoplasmic tail 
(L) with immune tyrosine based motifs (ITIM) permits 
the transduction of inhibitory signals and characterizes 
the inhibitory KIR (2DL, 3DL), which inhibit NK and cy-
totoxic T lymphocyte (CTL) mediated lysis of target cells 
expressing appropriate HLA class I ligands. In contrast, 
the presence of a short cytoplasmic tail (S) corresponds to 
the activating or non inhibitory KIR (2DS, 3DS), which 
may enhance cytolysis of target cells. KIR binding motifs 
to HLA-C are defined by a dimorphism in the α1 domain 
of the HLA-C heavy chain. HLA-C molecules with Ser77 
Asn80 are in Group C1 (-Cw1,-Cw3, -Cw7, -Cw8, -Cw12, 
-Cw14 and -Cw1601). HLA-C molecules with Asn77 Lys 
80 are in Group C2 (-Cw2, -Cw4, -Cw5, -Cw6, -Cw15, 
-Cw1602, -Cw17 and -Cw18)[6]. HLA-C1 allotypes are li-
gands for KIR2DL2/3 (inhibitory) and possibly KIR2DS2 
(activating), whereas HLA-C2 allotypes are bound by 
KIR2DL1 (inhibitory) and KIR2DS1 (activating).
KIR and HLA-C molecules play an essential role dur-
ing the development of NK cells, because functional 
maturation of NK cells requires specific interaction with 
MHC class I molecules. For example, NK cells that ex-
press MHC class I-specific inhibitory receptors have been 
found to be functionally reactive, but NK cells that lack 
MHC class I-specific inhibitory receptors are hyporeac-
tive to the same stimuli and do not exhibit cytotoxicity to 
Figure 2. Gel electrophoresis of PCR-SSP products of HLA-Cw*08/HLA-Cw*15 heterozygotes. M: Molecular mass marker.
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MHC class I-deficient target cells[22,23]. HLA class I and 
KIR genes are encoded on distinct chromosomes 6p21.3 
and 19q13.4 and inherited independently[24]. The indepen-
dent segregation of HLA and KIR genes raises the pos-
sibility that any given individual can express the receptor 
or the ligand only, or both receptor and ligand, so some 
individuals lack specific KIR-HLA receptor-ligand pair-
ings. Both the KIR receptor and its specific HLA ligand 
must be present in order to regulate NK cell activity, such 
that one without the other is functionally inert. It would 
be interesting to investigate the corresponding HLA class 
I ligands to determine whether their KIR interaction is im-
portant in disease progression. In this regard, we lay par-
ticular emphasis on the key polymorphic ligand/receptor 
to determine the relative contribution of inhibitory KIR2D 
genes and HLA-C alleles to IBD susceptibility.
In the present study, the KIR2DL1 and KIR2DL3 gene 
phenotype frequencies were significantly lower in UC 
patients than in healthy controls, and the KIR2DL1 gene 
phenotype frequency was significantly decreased in CD 
patients as compared with healthy controls. KIR2DL1-
HLA-C2 combination were significantly decreased in pa-
tients with UC and CD as compared with healthy controls. 
Regarding KIR2DL2/KIR2DL3-HLA-C1, we found no 
significant differences in gene frequencies in IBD patients 
as compared with healthy controls. Our results showed 
that IBD (UC and CD) susceptibility is mainly associated 
with a decrease in inhibitory KIR2DL1-HLA-C2 combi-
nations. 
The mechanisms by which KIR and HLA class I ligand 
genotypes influence susceptibility to autoimmune diseas-
es are not clear[25]. However, as NK cells are constitutive-
ly inhibited by self-HLA class I molecules, most studies 
emphasize that an imbalance of KIR and/or HLA class I 
ligands resulting in reduced inhibition or increased acti-
vation is the critical determinant[6]. Mono-KIR NK cells 
without the corresponding ligands in the individuals and 
NK cells lacking all inhibitory receptors behave self-tol-
erant. Reduced combinations of KIR2DL1 and HLA-C2 
in patients with UC and CD probably make NK cell and 
some killer T cell lack sufficently inhibitory signal, attack 
self cell, and finally result in autoimmune disease. Several 
of the genetic studies have suggested a model whereby 
inhibition of NK cells by some KIR-HLA combinations 
is stronger than others. In this model, the inhibition by 
KIR2DL1-HLA-C2 is strongest, followed by KIR2DL2-
HLA-C1, and finally KIR2DL3-HLA-C1[6,7,26,27]. Accord-
ingly, weaker inhibitory interactions result in greater NK 
cell activation and better protection from virus infection, 
or greater susceptibility to autoimmunity.
So KIR2DL2/L3-HLA-C1 should be more easily over-
ridden by activating signals than a stronger inhibitory 
interaction such as KIR2DL1-HLA-C2[7]. Environmental 
insults affecting the HLA-C1 ligand, such as infection-
mediated down regulation or masking of the iKIR-bind-
ing motif by a bound viral peptide, could promote the 
breakdown of self-tolerance and trigger autoimmunity in 
individuals carrying just one weakly iKIR + HLA combi-
nation. Interestingly, in our study, the majority of individ-
uals in UC and CD possessed the weaker KIR2DL2/3-C1 
as the only possible regulatory combination, lacking C2 
ligand for KIR2DL1. 
5  Conclusion
In this study, The susceptibility to IBD is mainly as-
sociated with a decrease in inhibitory KIR2DL1-HLA-C2 
combinations. The decrease of combination KIR2DL1 and 
HLA-C2 may reduce the activating threshold of NK cells 
and CTL, enhance the cytolytic activity of lymphocyte 
and promote its multiplication, and finally lead to immune 
response to self-organizations in IBD. KIR and HLA are 
highly polymorphism, interacting with eath other, various 
KIR and HLA comprise various compound. It is impor-
tant to explore various KIR-HLA compound in IBD.
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